In a phase 1/2 trial, patients with HER2 overexpressing ductal carcinoma in situ (DCIS) or early invasive BC received a HER2-pulsed DC vaccine via intranodal and/or intralesional injection prior to surgery (NCT02061332). Here, ERBB2 is linked to ductal breast carcinoma in situ.